Xenon Pharmaceuticals (XENE) Receivables - Net (2013 - 2025)

Xenon Pharmaceuticals (XENE) has 13 years of Receivables - Net data on file, last reported at $8.6 million in Q1 2025.

• Receivables - Net for Q1 2025 came in at $8.6 million, up 938.3% year-over-year; the trailing twelve-month figure through Mar 2025 was $8.6 million (up 938.3% YoY), and the FY2024 annual result was $1.5 million, up 68.08% from the prior year.
• Receivables - Net advanced to $8.6 million in Q1 2025 per XENE's latest filing, from $1.5 million in the prior quarter.
• Over five years, Receivables - Net peaked at $8.6 million in Q1 2025 and troughed at $805000.0 in Q3 2023.
• A 5-year average of $2.5 million and a median of $2.2 million in 2023 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2023 and 2025: Receivables - Net plunged 67.57% in 2023, then soared 938.3% in 2025.
• A 5-year view of Receivables - Net shows it stood at $2.8 million in 2021, then sank by 64.34% to $986000.0 in 2022, then declined by 11.36% to $874000.0 in 2023, then surged by 68.08% to $1.5 million in 2024, then jumped by 488.77% to $8.6 million in 2025.
• Business Quant data shows XENE's Receivables - Net at $8.6 million in Q1 2025, $1.5 million in Q4 2024, and $938000.0 in Q3 2024.